Aasim N Maldar1, Sanjeev Pattankar2, Basant K Misra2,3, Phulrenu H Chauhan4, Milind Sankhe2, Ketan Desai2, N F Shah1. 1. Department of Endocrinology, P.D. Hinduja Hospital and Medical Research Center, Mumbai, 400016, India. 2. Department of Neurosurgery & Gamma Knife Radiosurgery, P.D. Hinduja Hospital and Medical Research Center, Mumbai, 400016, India. 3. Department of Surgery, P.D. Hinduja Hospital and Medical Research Center, Mumbai, 400016, India. 4. Department of Endocrinology, P.D. Hinduja Hospital and Medical Research Center, Mumbai, 400016, India. chauhanph@rediffmail.com.
Abstract
PURPOSE: Gamma Knife Radiosurgery(GKRS) is an established modality for treatment of non-functioning pituitary adenomas(NFPA). The objective of the study was to assess long-term hormonal and imaging outcomes after adjunctive GKRS in patients with NFPA. METHODS: A retrospective review of records of 109 patients with NFPA, from 1996 to 2020, who received adjunctive GKRS, was performed. Patients who had received GKRS as the primary modality of treatment for NFPA were not included. RESULTS: Sixty-three (57.8%) patients were available for follow up at our institute. The median follow-up period was 47 months (range, 6-260). At a median time of 38 months (range, 8-97), 25 (39.7%) patients developed ≥ 1 new pituitary hormone deficiency. Median time to cortisol deficiency was 38 months (range, 8-55), thyroid hormone deficiency was 45.5 months (range, 12-97) and gonadotropin deficiency was 45 months (range, 21-75). The actuarial risk of developing a new pituitary hormone deficit at 1, 3, 5, 7, and 10 years was 2.5%, 11%, 26.3%, 28% and 29.7%, respectively. Adenoma size decreased in 36 (57.1%) patients, remained unchanged in 19 (30.2%) patients, and increased in 8 (12.7%) patients. Overall tumor control rate was 87.3%. Endocrinopathy-Free Survival was 47.1%, and tumor Progression-Free Survival was 93.3%, at 5 years. Five (4.6%) patients required additional treatment after GKRS. One (1.6%) patient each had worsening of headache, optic atrophy and cerebellar infarct after GKRS therapy. CONCLUSION: GKRS offers a safe adjunctive treatment modality, with satisfactory long-term preservation of hormone functions and a high rate of tumor control, in patients with NFPA.
PURPOSE: Gamma Knife Radiosurgery(GKRS) is an established modality for treatment of non-functioning pituitary adenomas(NFPA). The objective of the study was to assess long-term hormonal and imaging outcomes after adjunctive GKRS in patients with NFPA. METHODS: A retrospective review of records of 109 patients with NFPA, from 1996 to 2020, who received adjunctive GKRS, was performed. Patients who had received GKRS as the primary modality of treatment for NFPA were not included. RESULTS: Sixty-three (57.8%) patients were available for follow up at our institute. The median follow-up period was 47 months (range, 6-260). At a median time of 38 months (range, 8-97), 25 (39.7%) patients developed ≥ 1 new pituitary hormone deficiency. Median time to cortisol deficiency was 38 months (range, 8-55), thyroid hormone deficiency was 45.5 months (range, 12-97) and gonadotropin deficiency was 45 months (range, 21-75). The actuarial risk of developing a new pituitary hormone deficit at 1, 3, 5, 7, and 10 years was 2.5%, 11%, 26.3%, 28% and 29.7%, respectively. Adenoma size decreased in 36 (57.1%) patients, remained unchanged in 19 (30.2%) patients, and increased in 8 (12.7%) patients. Overall tumor control rate was 87.3%. Endocrinopathy-Free Survival was 47.1%, and tumor Progression-Free Survival was 93.3%, at 5 years. Five (4.6%) patients required additional treatment after GKRS. One (1.6%) patient each had worsening of headache, optic atrophy and cerebellar infarct after GKRS therapy. CONCLUSION: GKRS offers a safe adjunctive treatment modality, with satisfactory long-term preservation of hormone functions and a high rate of tumor control, in patients with NFPA.
Authors: Jason P Sheehan; Robert M Starke; David Mathieu; Byron Young; Penny K Sneed; Veronica L Chiang; John Y K Lee; Hideyuki Kano; Kyung-Jae Park; Ajay Niranjan; Douglas Kondziolka; Gene H Barnett; Stephen Rush; John G Golfinos; L Dade Lunsford Journal: J Neurosurg Date: 2013-04-26 Impact factor: 5.115
Authors: Kyung-Jae Park; Hideyuki Kano; Phillip V Parry; Ajay Niranjan; John C Flickinger; L Dade Lunsford; Douglas Kondziolka Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: Emanuele Ferrante; Monica Ferraroni; Tristana Castrignanò; Laura Menicatti; Mascia Anagni; Giuseppe Reimondo; Patrizia Del Monte; Donatella Bernasconi; Paola Loli; Marco Faustini-Fustini; Giorgio Borretta; Massimo Terzolo; Marco Losa; Alberto Morabito; Anna Spada; Paolo Beck-Peccoz; Andrea G Lania Journal: Eur J Endocrinol Date: 2006-12 Impact factor: 6.664
Authors: Bruce E Pollock; Joseph Cochran; Neena Natt; Paul D Brown; Dana Erickson; Michael J Link; Yolanda I Garces; Robert L Foote; Scott L Stafford; Paula J Schomberg Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-29 Impact factor: 7.038
Authors: Edward F Chang; Michael E Sughrue; Gabriel Zada; Charles B Wilson; Lewis S Blevins; Sandeep Kunwar Journal: Pituitary Date: 2010-09 Impact factor: 4.107